SCP
HAE icon

Sandhill Capital Partners’s Haemonetics HAE Stock Holding History

Sandhill Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-114,416
Closed -$4.73M – 93
2013
Q2 		$4.73M Buy
+114,416
New +$4.63M 2.34% 22

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sandhill Capital Partners's HAE Position: Q3 2013 in Review

Sandhill Capital Partners sold out of Haemonetics (HAE) in Q3 2013, closing a stake of 114,416 shares — an estimated $4.73M sold.

Sandhill Capital Partners first reported a position in HAE in Q2 2013 and held it in 1 quarter. The position peaked at $4.73M in Q2 2013. 192 funds tracked by Wall St. Rank hold HAE as of Q3 2013.

  • Sandhill Capital Partners reported no remaining Haemonetics position as of Q3 2013 after selling out during the quarter.
  • Sandhill Capital Partners sold 114,416 Haemonetics shares in Q3 2013, an estimated $4.73M.
  • Sandhill Capital Partners first reported a position in Haemonetics in Q2 2013 and held it in 1 quarter.
  • Sandhill Capital Partners's Haemonetics position peaked at $4.73M in Q2 2013.
  • 192 funds tracked by Wall St. Rank held Haemonetics as of Q3 2013.

Based on Sandhill Capital Partners's 13F filing for Q3 2013, filed 21 Nov 2013.